

From: Jessica Bulliss <pharma@smiconferences.co.uk>

To: Kester, Tonykester@aging.sc.gov

Date: 9/26/2016 11:23:05 AM

Subject: Big Pharma Discuss Antibacterial Resistance in Exclusive New Interviews | Includes Pfizer, Janssen and more

## Interviews Released on Antibiotic Resistance with Pfizer, Janssen, Blueberry Therapeutics and BARDA - [Read them here](#)

Superbugs & Superdrugs USA 2016 - *\$200 early bird ends 30th Sept*  
Conference: Nov 14th & 15th | Two Interactive Workshops: Nov 16th  
Renaissance Woodbridge Hotel, Iselin, New Jersey

[Register](#) | [Brochure](#) | [Get in touch](#)

---

Dear Mr Tony Kester,

SMi Group have released an exclusive series of interviews ahead of the [Superbugs & Superdrugs USA](#) Conference that will take place on **Nov 14th and 15th 2016**.

Running for 18 years in Europe, SMi Group's Superbugs & Superdrugs event will travel across the Atlantic Ocean for the first time to Iselin New Jersey following a high attendance of US delegates at the European shows.

The popularity of the event highlights the imminent global threat of antimicrobial resistance and the urgency for scientists and drug developers to discover new alternatives to bacteria resistant treatments.

The **interviews released** this week with 4 of the keynote speakers are available to read in the event [download centre](#).

---

**Will you be joining us this November?** If you haven't made a decision yet, here are 3 key reasons to attend:

### 1. CONTENT

This year's event will provide a comprehensive overview of current issues and ongoing considerations on infectious disease and AMR to both new and seasoned stakeholders. The packed agenda features:

- Over 17 thought provoking presentations from industry thought leaders Spotlight sessions on novel antibacterial therapeutics
- Guidance on strengthening the antibiotic pipeline
- New breakthroughs through big pharma case studies
- Insight into funding opportunities

### 2. INDUSTRY PROFESSIONALS UNDER 1 ROOF

#### DOWNLOAD BROCHURE

---

#### Sponsored by:

Noigel LLC and Polyphor

---

#### How to Register:

**\$200 saving ends  
Sept 30th**

Register online at:  
[www.superbugs-usa.com](http://www.superbugs-usa.com)

Sponsorship opportunities:  
Contact Alia Malick  
+44 (0)20 7827 6168  
[amalick@smi-online.co.uk](mailto:amalick@smi-online.co.uk)

Delegate enquiries:  
Contact Matthew Apps  
+44 (0)20 7827 6093  
[mapps@smi-online.co.uk](mailto:mapps@smi-online.co.uk)

---

**This is why Superbugs & Superdrugs USA is a must-attend event:**

*"I'm particularly looking forward to the session on **public/private partnerships**. We are entering into a new phase where the prospects for antimicrobial therapy may seem bleak however, these may offer tremendous promise*

With **3+ hours of networking**, Superbugs & Superdrugs USA provides a perfect platform to build strategic partnerships and secure future collaborations.

**Attendee's include:** ABAC Therapeutics, Allegra Therapeutics, AstraZeneca, BARDA, Blueberry Therapeutics, Bugworks Research India, CUBRC, Destiny Pharma, Entasis Therapeutics, Janssen Research & Development, JSC R-PHARM, Micromyx, Modern Medical PC, Motif BioSciences, National Institute Of Allergy & Infectious Diseases, NeoSome Life Sciences, Noigel, Pan American Health Organization (PAHO), Pfizer Antibacterials, Phico Therapeutics, Polyphor, Sanderling Consulting, Spero Therapeutics, The Medicines Company, University of North Texas Health Science Center, Venaticus AB, Zoetis, + more...

Add your name to the list

### 3. TWO INTERACTIVE WORKSHOPS

Wait...there's more! Don't miss the chance to receive hands on training through our exclusive post conference **workshops** taking place on **Nov 16th 2016**.

#### WORKSHOP A | 08:30 - 12:30

The Use of Animal Models in Pre-Clinical Drug Development

Hosted by the **UNT Health Science Center**.

Led by **William Weiss**, Director - Pre-Clinical Services; and **Mark Pulse**, Associate Director, Pre-Clinical Services.

#### WORKSHOP B | 13:30 - 17:30

Opportunities & Challenges in the Development of New Antibacterial Therapeutics

Hosted by **The National Institute of Allergy and Infectious Diseases**.

Led by **Dr Tina Guina** Therapeutics Development Project Officer, **Dr Francois Franceschi** Therapeutics Development Program Officer

Visit the **website** for further information or **contact us** today to arrange a **VIP package** to attend all 3 days.

We look forward to welcoming you when doors open this fall.

Kind Regards,

The Superbugs USA Team

*for the future of antibacterial development" - Pfizer*

*"The three sessions focused on **novel platforms** and agents in the treatment and **prevention** of diseases caused by so-called 'Superbugs' are all of interest as they cover a broad spectrum of alternate approaches and it's always good to be cognizant of new science and potential opportunities." - Janssen*

*"I'm looking forward to the section on "**Strengthening the Pipeline**" and hearing about the other work going on in developing **beta-lactamase inhibitors**." - Blueberry Therapeutics*

[www.superbugs-usa.com](http://www.superbugs-usa.com)

You are registered as: [kester@aging.sc.gov](mailto:kester@aging.sc.gov) Your Unique Reference Number: 92804565  
To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>